speb/financial-data huggingface dataset:
PHAR.L balance_sheet (annual, 2022-12-31) — Properties: 1119100000.00
PHAR.L cash_flow (annual, 2022-12-31) — Purchase Of Business: 0.00
PHAR.L cash_flow (annual, 2022-12-31) — Purchase Of Intangibles: -4400000.00
PHAR.L cash_flow (annual, 2022-12-31) — Purchase Of PPE: -25400000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Raw Materials: 7200000.00
PHAR.L income_statement (annual, 2022-12-31) — Reconciled Cost Of Revenue: 116800000.00
PHAR.L income_statement (annual, 2022-12-31) — Reconciled Depreciation: 55200000.00
PHAR.L cash_flow (annual, 2022-12-31) — Repayment Of Debt: -27100000.00
PHAR.L cash_flow (annual, 2022-12-31) — Repurchase Of Capital Stock: -2900000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Restricted Cash: 7400000.00
PHAR.L income_statement (annual, 2022-12-31) — Restructuring And Mergern Acquisition: 800000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Retained Earnings: -15300000.00
PHAR.L cash_flow (annual, 2022-12-31) — Sale Of Business: 18400000.00
PHAR.L income_statement (annual, 2022-12-31) — Selling General And Administration: 10000000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Share Issued: 441795126.00
PHAR.L cash_flow (annual, 2022-12-31) — Short Term Debt Issuance: 16700000.00
PHAR.L income_statement (annual, 2022-12-31) — Special Income Charges: 20500000.00
PHAR.L cash_flow (annual, 2022-12-31) — Stock Based Compensation: 1300000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Stockholders Equity: 330600000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Tangible Book Value: 330600000.00
PHAR.L income_statement (annual, 2022-12-31) — Tax Effect Of Unusual Items: 3952000.00
PHAR.L income_statement (annual, 2022-12-31) — Tax Provision: 56200000.00
PHAR.L income_statement (annual, 2022-12-31) — Tax Rate For Calcs: 0.19
PHAR.L balance_sheet (annual, 2022-12-31) — Taxes Receivable: 2100000.00
PHAR.L cash_flow (annual, 2022-12-31) — Taxes Refund Paid: -54700000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Total Assets: 572900000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Total Capitalization: 365200000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Total Debt: 75000000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Total Equity Gross Minority Interest: 330600000.00
PHAR.L income_statement (annual, 2022-12-31) — Total Expenses: 126800000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Total Liabilities Net Minority Interest: 242300000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Total Non Current Assets: 457400000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Total Non Current Liabilities Net Minority Interest: 183200000.00
PHAR.L income_statement (annual, 2022-12-31) — Total Operating Income As Reported: 100200000.00
PHAR.L income_statement (annual, 2022-12-31) — Total Other Finance Cost: 4100000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Total Tax Payable: 5200000.00
PHAR.L income_statement (annual, 2022-12-31) — Total Unusual Items: 20800000.00
PHAR.L income_statement (annual, 2022-12-31) — Total Unusual Items Excluding Goodwill: 20800000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Tradeand Other Payables Non Current: 900000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Treasury Shares Number: 11249125.00
PHAR.L balance_sheet (annual, 2022-12-31) — Treasury Stock: 42700000.00
PHAR.L balance_sheet (annual, 2022-12-31) — Working Capital: 56400000.00
PHAR.L income_statement (annual, 2022-12-31) — Write Off: 0.00
PHAR.L income_statement (annual, 2023-12-31) — +Operating Expense: 9400000.00
PHAR.L income_statement (annual, 2023-12-31) — +Total Revenue: 167900000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Accounts Receivable: 50800000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Accumulated Depreciation: -835600000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Additional Paid In Capital: 159500000.00
PHAR.L income_statement (annual, 2023-12-31) — Average Dilution Earnings: 0.00
PHAR.L income_statement (annual, 2023-12-31) — Basic Average Shares: 427200000.00
PHAR.L income_statement (annual, 2023-12-31) — Basic EPS: -0.11
PHAR.L cash_flow (annual, 2023-12-31) — Beginning Cash Position: 45300000.00
PHAR.L cash_flow (annual, 2023-12-31) — Capital Expenditure: -23200000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Capital Lease Obligations: 500000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Capital Stock: 33700000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Cash And Cash Equivalents: 31400000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Cash Cash Equivalents And Short Term Investments: 31400000.00
PHAR.L cash_flow (annual, 2023-12-31) — Cash Dividends Paid: -5600000.00
PHAR.L cash_flow (annual, 2023-12-31) — Change In Inventory: 3900000.00
PHAR.L cash_flow (annual, 2023-12-31) — Change In Payable: 200000.00
PHAR.L cash_flow (annual, 2023-12-31) — Change In Receivables: -19100000.00
PHAR.L cash_flow (annual, 2023-12-31) — Change In Working Capital: -15000000.00
PHAR.L cash_flow (annual, 2023-12-31) — Changes In Cash: -11800000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Common Stock: 33700000.00
PHAR.L cash_flow (annual, 2023-12-31) — Common Stock Dividend Paid: -5600000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Common Stock Equity: 275200000.00
PHAR.L cash_flow (annual, 2023-12-31) — Common Stock Issuance: 0.00
PHAR.L cash_flow (annual, 2023-12-31) — Common Stock Payments: -2800000.00
PHAR.L income_statement (annual, 2023-12-31) — Cost Of Revenue: 111200000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Current Assets: 100400000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Current Capital Lease Obligation: 300000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Current Debt: 29500000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Current Debt And Capital Lease Obligation: 29800000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Current Liabilities: 48100000.00
PHAR.L cash_flow (annual, 2023-12-31) — Depreciation: 55600000.00
PHAR.L cash_flow (annual, 2023-12-31) — Depreciation And Amortization: 55600000.00
PHAR.L income_statement (annual, 2023-12-31) — Diluted Average Shares: 427200000.00
PHAR.L income_statement (annual, 2023-12-31) — Diluted EPS: -0.11
PHAR.L income_statement (annual, 2023-12-31) — Diluted NI Availto Com Stockholders: -48800000.00
PHAR.L cash_flow (annual, 2023-12-31) — Dividends Received Cfi: 0.00
PHAR.L income_statement (annual, 2023-12-31) — EBIT: -19300000.00
PHAR.L income_statement (annual, 2023-12-31) — EBITDA: 36300000.00
PHAR.L cash_flow (annual, 2023-12-31) — Effect Of Exchange Rate Changes: -900000.00
PHAR.L cash_flow (annual, 2023-12-31) — End Cash Position: 32600000.00
PHAR.L cash_flow (annual, 2023-12-31) — Financing Cash Flow: -50100000.00
PHAR.L cash_flow (annual, 2023-12-31) — Free Cash Flow: 21700000.00
PHAR.L income_statement (annual, 2023-12-31) — General And Administrative Expense: 9000000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Gross PPE: 1134100000.00
PHAR.L income_statement (annual, 2023-12-31) — Gross Profit: 56700000.00
PHAR.L income_statement (annual, 2023-12-31) — Impairment Of Capital Assets: 65400000.00
PHAR.L income_statement (annual, 2023-12-31) — Interest Expense: 9700000.00
PHAR.L income_statement (annual, 2023-12-31) — Interest Expense Non Operating: 9700000.00
PHAR.L cash_flow (annual, 2023-12-31) — Interest Paid Cff: -6400000.00
PHAR.L cash_flow (annual, 2023-12-31) — Interest Received Cfo: 400000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Inventory: 3300000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Invested Capital: 315700000.00
PHAR.L cash_flow (annual, 2023-12-31) — Investing Cash Flow: -6600000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Investmentsin Subsidiariesat Cost: 0.00
PHAR.L cash_flow (annual, 2023-12-31) — Issuance Of Capital Stock: 0.00
PHAR.L cash_flow (annual, 2023-12-31) — Issuance Of Debt: 9200000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Long Term Capital Lease Obligation: 200000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Long Term Debt: 11000000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Long Term Debt And Capital Lease Obligation: 11200000.00
PHAR.L cash_flow (annual, 2023-12-31) — Long Term Debt Payments: -44200000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Long Term Equity Investment: 0.00
PHAR.L balance_sheet (annual, 2023-12-31) — Long Term Provisions: 53800000.00
PHAR.L cash_flow (annual, 2023-12-31) — Net Common Stock Issuance: -2800000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Net Debt: 9100000.00
PHAR.L income_statement (annual, 2023-12-31) — Net Income: -48800000.00
PHAR.L income_statement (annual, 2023-12-31) — Net Income Common Stockholders: -48800000.00
PHAR.L income_statement (annual, 2023-12-31) — Net Income Continuous Operations: -48800000.00
PHAR.L income_statement (annual, 2023-12-31) — Net Income From Continuing And Discontinued Operation: -48800000.00
PHAR.L income_statement (annual, 2023-12-31) — Net Income From Continuing Operation Net Minority Interest: -48800000.00
PHAR.L cash_flow (annual, 2023-12-31) — Net Income From Continuing Operations: -18100000.00
PHAR.L income_statement (annual, 2023-12-31) — Net Income Including Noncontrolling Interests: -48800000.00
PHAR.L cash_flow (annual, 2023-12-31) — Net Intangibles Purchase And Sale: -9700000.00
PHAR.L income_statement (annual, 2023-12-31) — Net Interest Income: -9700000.00
PHAR.L cash_flow (annual, 2023-12-31) — Net Issuance Payments Of Debt: -35000000.00
PHAR.L cash_flow (annual, 2023-12-31) — Net Long Term Debt Issuance: -44200000.00
PHAR.L income_statement (annual, 2023-12-31) — Net Non Operating Interest Income Expense: -9700000.00
PHAR.L cash_flow (annual, 2023-12-31) — Net Other Investing Changes: 16600000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Net PPE: 298500000.00
PHAR.L cash_flow (annual, 2023-12-31) — Net PPE Purchase And Sale: -13500000.00
PHAR.L cash_flow (annual, 2023-12-31) — Net Short Term Debt Issuance: 9200000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Net Tangible Assets: 275200000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Non Current Deferred Taxes Liabilities: 68200000.00
PHAR.L income_statement (annual, 2023-12-31) — Normalized EBITDA: 102600000.00
PHAR.L income_statement (annual, 2023-12-31) — Normalized Income: 4903000.00
PHAR.L cash_flow (annual, 2023-12-31) — Operating Cash Flow: 44900000.00
PHAR.L income_statement (annual, 2023-12-31) — Operating Income: 47300000.00
PHAR.L income_statement (annual, 2023-12-31) — Operating Revenue: 167900000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Ordinary Shares Number: 420777818.00
PHAR.L balance_sheet (annual, 2023-12-31) — Other Current Assets: 100000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Other Equity Interest: 2400000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Other Investments: 4900000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Other Non Current Assets: -500000.00
PHAR.L income_statement (annual, 2023-12-31) — Other Operating Expenses: 400000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Other Payable: 9600000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Other Properties: 1300000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Other Receivables: 11400000.00
PHAR.L income_statement (annual, 2023-12-31) — Otherunder Preferred Stock Dividend: 0.00
PHAR.L balance_sheet (annual, 2023-12-31) — Payables: 15400000.00
PHAR.L income_statement (annual, 2023-12-31) — Pretax Income: -29000000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Properties: 1132800000.00
PHAR.L cash_flow (annual, 2023-12-31) — Purchase Of Intangibles: -9700000.00
PHAR.L cash_flow (annual, 2023-12-31) — Purchase Of PPE: -13500000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Raw Materials: 3300000.00
PHAR.L income_statement (annual, 2023-12-31) — Reconciled Cost Of Revenue: 111200000.00
PHAR.L income_statement (annual, 2023-12-31) — Reconciled Depreciation: 55600000.00
PHAR.L cash_flow (annual, 2023-12-31) — Repayment Of Debt: -44200000.00
PHAR.L cash_flow (annual, 2023-12-31) — Repurchase Of Capital Stock: -2800000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Restricted Cash: 1200000.00
PHAR.L income_statement (annual, 2023-12-31) — Restructuring And Mergern Acquisition: 600000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Retained Earnings: -71900000.00
PHAR.L income_statement (annual, 2023-12-31) — Selling General And Administration: 9000000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Share Issued: 432026943.00
PHAR.L cash_flow (annual, 2023-12-31) — Short Term Debt Issuance: 9200000.00
PHAR.L income_statement (annual, 2023-12-31) — Special Income Charges: -66000000.00
PHAR.L cash_flow (annual, 2023-12-31) — Stock Based Compensation: 900000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Stockholders Equity: 275200000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Tangible Book Value: 275200000.00
PHAR.L income_statement (annual, 2023-12-31) — Tax Effect Of Unusual Items: -12597000.00
PHAR.L income_statement (annual, 2023-12-31) — Tax Provision: 19800000.00
PHAR.L income_statement (annual, 2023-12-31) — Tax Rate For Calcs: 0.19
PHAR.L balance_sheet (annual, 2023-12-31) — Taxes Receivable: 2200000.00
PHAR.L cash_flow (annual, 2023-12-31) — Taxes Refund Paid: -44300000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Total Assets: 457000000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Total Capitalization: 286200000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Total Debt: 41000000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Total Equity Gross Minority Interest: 275200000.00
PHAR.L income_statement (annual, 2023-12-31) — Total Expenses: 120600000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Total Liabilities Net Minority Interest: 181800000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Total Non Current Assets: 356600000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Total Non Current Liabilities Net Minority Interest: 133700000.00
PHAR.L income_statement (annual, 2023-12-31) — Total Operating Income As Reported: -18100000.00
PHAR.L income_statement (annual, 2023-12-31) — Total Other Finance Cost: 1300000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Total Tax Payable: 5800000.00
PHAR.L income_statement (annual, 2023-12-31) — Total Unusual Items: -66300000.00
PHAR.L income_statement (annual, 2023-12-31) — Total Unusual Items Excluding Goodwill: -66300000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Tradeand Other Payables Non Current: 500000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Treasury Shares Number: 11249125.00
PHAR.L balance_sheet (annual, 2023-12-31) — Treasury Stock: 42600000.00
PHAR.L balance_sheet (annual, 2023-12-31) — Working Capital: 52300000.00
PHAR.L income_statement (annual, 2024-12-31) — +Operating Expense: 10500000.00
PHAR.L income_statement (annual, 2024-12-31) — +Total Revenue: 136000000.00
PHAR.L balance_sheet (annual, 2024-12-31) — Accounts Receivable: 40500000.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Accounts Receivable: 40500000.00
PHAR.L balance_sheet (annual, 2024-12-31) — Accumulated Depreciation: -854600000.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Accumulated Depreciation: -854600000.00
PHAR.L balance_sheet (annual, 2024-12-31) — Additional Paid In Capital: 160100000.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Additional Paid In Capital: 160100000.00
PHAR.L income_statement (annual, 2024-12-31) — Average Dilution Earnings: -900000.00
PHAR.L income_statement (annual, 2024-12-31) — Basic Average Shares: 417000000.00
PHAR.L income_statement (annual, 2024-12-31) — Basic EPS: 0.06
PHAR.L cash_flow (annual, 2024-12-31) — Beginning Cash Position: 32600000.00
PHAR.L cash_flow (annual, 2024-12-31) — Capital Expenditure: -23800000.00
PHAR.L balance_sheet (annual, 2024-12-31) — Capital Lease Obligations: 200000.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Capital Lease Obligations: 200000.00
PHAR.L balance_sheet (annual, 2024-12-31) — Capital Stock: 33100000.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Capital Stock: 33100000.00
PHAR.L balance_sheet (annual, 2024-12-31) — Cash And Cash Equivalents: 16400000.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Cash And Cash Equivalents: 16400000.00
PHAR.L balance_sheet (annual, 2024-12-31) — Cash Cash Equivalents And Short Term Investments: 16400000.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Cash Cash Equivalents And Short Term Investments: 16400000.00
PHAR.L cash_flow (annual, 2024-12-31) — Cash Dividends Paid: -5900000.00
PHAR.L cash_flow (annual, 2024-12-31) — Change In Inventory: -6000000.00
PHAR.L cash_flow (annual, 2024-12-31) — Change In Payable: -300000.00
PHAR.L cash_flow (annual, 2024-12-31) — Change In Receivables: 11300000.00
PHAR.L cash_flow (annual, 2024-12-31) — Change In Working Capital: 5000000.00
PHAR.L cash_flow (annual, 2024-12-31) — Changes In Cash: -15500000.00
PHAR.L balance_sheet (annual, 2024-12-31) — Common Stock: 33100000.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Common Stock: 33100000.00
PHAR.L cash_flow (annual, 2024-12-31) — Common Stock Dividend Paid: -5900000.00
PHAR.L balance_sheet (annual, 2024-12-31) — Common Stock Equity: 295700000.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Common Stock Equity: 295700000.00
PHAR.L cash_flow (annual, 2024-12-31) — Common Stock Payments: -3800000.00
PHAR.L income_statement (annual, 2024-12-31) — Cost Of Revenue: 87300000.00
PHAR.L balance_sheet (annual, 2024-12-31) — Current Assets: 74000000.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Current Assets: 74000000.00
PHAR.L balance_sheet (annual, 2024-12-31) — Current Capital Lease Obligation: 200000.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Current Capital Lease Obligation: 200000.00
PHAR.L balance_sheet (annual, 2024-12-31) — Current Debt: 0.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Current Debt: 0.00
PHAR.L balance_sheet (annual, 2024-12-31) — Current Debt And Capital Lease Obligation: 200000.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Current Debt And Capital Lease Obligation: 200000.00
PHAR.L balance_sheet (annual, 2024-12-31) — Current Liabilities: 17700000.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Current Liabilities: 17700000.00
PHAR.L cash_flow (annual, 2024-12-31) — Depreciation: 47300000.00
PHAR.L cash_flow (annual, 2024-12-31) — Depreciation And Amortization: 47300000.00
PHAR.L income_statement (annual, 2024-12-31) — Diluted Average Shares: 419700000.00
PHAR.L income_statement (annual, 2024-12-31) — Diluted EPS: 0.05
PHAR.L income_statement (annual, 2024-12-31) — Diluted NI Availto Com Stockholders: 22700000.00
PHAR.L cash_flow (annual, 2024-12-31) — Dividends Received Cfi: 0.00
PHAR.L income_statement (annual, 2024-12-31) — EBIT: 64000000.00
PHAR.L income_statement (annual, 2024-12-31) — EBITDA: 111300000.00
PHAR.L cash_flow (annual, 2024-12-31) — Effect Of Exchange Rate Changes: -600000.00
PHAR.L cash_flow (annual, 2024-12-31) — End Cash Position: 16500000.00
PHAR.L cash_flow (annual, 2024-12-31) — Financing Cash Flow: -51600000.00
PHAR.L cash_flow (annual, 2024-12-31) — Free Cash Flow: 30200000.00
PHAR.L income_statement (annual, 2024-12-31) — General And Administrative Expense: 9100000.00
PHAR.L balance_sheet (annual, 2024-12-31) — Gross PPE: 1150300000.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Gross PPE: 1150300000.00
PHAR.L income_statement (annual, 2024-12-31) — Gross Profit: 48700000.00
PHAR.L balance_sheet (annual, 2024-12-31) — Hedging Assets Current: 100000.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Hedging Assets Current: 100000.00
PHAR.L income_statement (annual, 2024-12-31) — Impairment Of Capital Assets: -26300000.00
PHAR.L income_statement (annual, 2024-12-31) — Interest Expense: 3300000.00
PHAR.L income_statement (annual, 2024-12-31) — Interest Expense Non Operating: 3300000.00
PHAR.L cash_flow (annual, 2024-12-31) — Interest Paid Cff: -2400000.00
PHAR.L cash_flow (annual, 2024-12-31) — Interest Paid Cfo: 0.00
PHAR.L cash_flow (annual, 2024-12-31) — Interest Received Cfo: 400000.00
PHAR.L balance_sheet (annual, 2024-12-31) — Inventory: 9300000.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Inventory: 9300000.00
PHAR.L balance_sheet (annual, 2024-12-31) — Invested Capital: 295700000.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Invested Capital: 295700000.00
PHAR.L cash_flow (annual, 2024-12-31) — Investing Cash Flow: -17900000.00
PHAR.L balance_sheet (annual, 2024-12-31) — Investmentsin Subsidiariesat Cost: 0.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Investmentsin Subsidiariesat Cost: 0.00
PHAR.L cash_flow (annual, 2024-12-31) — Issuance Of Debt: 2200000.00
PHAR.L balance_sheet (annual, 2024-12-31) — Long Term Capital Lease Obligation: 0.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Long Term Capital Lease Obligation: 0.00
PHAR.L balance_sheet (annual, 2024-12-31) — Long Term Debt: 0.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Long Term Debt: 0.00
PHAR.L balance_sheet (annual, 2024-12-31) — Long Term Debt And Capital Lease Obligation: 0.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Long Term Debt And Capital Lease Obligation: 0.00
PHAR.L cash_flow (annual, 2024-12-31) — Long Term Debt Payments: -41400000.00
PHAR.L balance_sheet (annual, 2024-12-31) — Long Term Equity Investment: 0.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Long Term Equity Investment: 0.00
PHAR.L balance_sheet (annual, 2024-12-31) — Long Term Provisions: 51100000.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Long Term Provisions: 51100000.00
PHAR.L cash_flow (annual, 2024-12-31) — Net Business Purchase And Sale: 0.00
PHAR.L cash_flow (annual, 2024-12-31) — Net Common Stock Issuance: -3800000.00
PHAR.L income_statement (annual, 2024-12-31) — Net Income: 23600000.00
PHAR.L income_statement (annual, 2024-12-31) — Net Income Common Stockholders: 23600000.00
PHAR.L income_statement (annual, 2024-12-31) — Net Income Continuous Operations: 23600000.00
PHAR.L income_statement (annual, 2024-12-31) — Net Income From Continuing And Discontinued Operation: 23600000.00
PHAR.L income_statement (annual, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: 23600000.00
PHAR.L cash_flow (annual, 2024-12-31) — Net Income From Continuing Operations: 64300000.00
PHAR.L income_statement (annual, 2024-12-31) — Net Income Including Noncontrolling Interests: 23600000.00
PHAR.L cash_flow (annual, 2024-12-31) — Net Intangibles Purchase And Sale: -5400000.00
PHAR.L income_statement (annual, 2024-12-31) — Net Interest Income: -3300000.00
PHAR.L cash_flow (annual, 2024-12-31) — Net Issuance Payments Of Debt: -39200000.00
PHAR.L cash_flow (annual, 2024-12-31) — Net Long Term Debt Issuance: -41400000.00
PHAR.L income_statement (annual, 2024-12-31) — Net Non Operating Interest Income Expense: -3300000.00
PHAR.L cash_flow (annual, 2024-12-31) — Net Other Investing Changes: 5900000.00
PHAR.L balance_sheet (annual, 2024-12-31) — Net PPE: 295700000.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Net PPE: 295700000.00
PHAR.L cash_flow (annual, 2024-12-31) — Net PPE Purchase And Sale: -18400000.00
PHAR.L cash_flow (annual, 2024-12-31) — Net Short Term Debt Issuance: 2200000.00
PHAR.L balance_sheet (annual, 2024-12-31) — Net Tangible Assets: 295700000.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Net Tangible Assets: 295700000.00
PHAR.L balance_sheet (annual, 2024-12-31) — Non Current Deferred Taxes Liabilities: 62600000.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Non Current Deferred Taxes Liabilities: 62600000.00
PHAR.L income_statement (annual, 2024-12-31) — Normalized EBITDA: 85300000.00
PHAR.L income_statement (annual, 2024-12-31) — Normalized Income: 4100000.00
PHAR.L cash_flow (annual, 2024-12-31) — Operating Cash Flow: 54000000.00
PHAR.L income_statement (annual, 2024-12-31) — Operating Income: 38200000.00
PHAR.L income_statement (annual, 2024-12-31) — Operating Revenue: 136000000.00
PHAR.L balance_sheet (annual, 2024-12-31) — Ordinary Shares Number: 411271988.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Ordinary Shares Number: 411271988.00
PHAR.L balance_sheet (annual, 2024-12-31) — Other Current Assets: 100000.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Other Current Assets: 100000.00
PHAR.L balance_sheet (annual, 2024-12-31) — Other Equity Interest: 3200000.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Other Equity Interest: 3200000.00
PHAR.L balance_sheet (annual, 2024-12-31) — Other Investments: 1800000.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Other Investments: 1800000.00
PHAR.L balance_sheet (annual, 2024-12-31) — Other Non Current Assets: -200000.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Other Non Current Assets: -200000.00
PHAR.L income_statement (annual, 2024-12-31) — Other Operating Expenses: 800000.00
PHAR.L balance_sheet (annual, 2024-12-31) — Other Payable: 8000000.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Other Payable: 8000000.00
PHAR.L balance_sheet (annual, 2024-12-31) — Other Properties: 1300000.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Other Properties: 1300000.00
PHAR.L balance_sheet (annual, 2024-12-31) — Other Receivables: 7300000.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Other Receivables: 7300000.00
PHAR.L income_statement (annual, 2024-12-31) — Otherunder Preferred Stock Dividend: 0.00
PHAR.L balance_sheet (annual, 2024-12-31) — Payables: 13300000.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Payables: 13300000.00
PHAR.L income_statement (annual, 2024-12-31) — Pretax Income: 60700000.00
PHAR.L balance_sheet (annual, 2024-12-31) — Properties: 1149000000.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Properties: 1149000000.00
PHAR.L cash_flow (annual, 2024-12-31) — Purchase Of Business: 0.00
PHAR.L cash_flow (annual, 2024-12-31) — Purchase Of Intangibles: -5400000.00
PHAR.L cash_flow (annual, 2024-12-31) — Purchase Of PPE: -18400000.00
PHAR.L balance_sheet (annual, 2024-12-31) — Raw Materials: 9300000.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Raw Materials: 9300000.00
PHAR.L income_statement (annual, 2024-12-31) — Reconciled Cost Of Revenue: 87300000.00
PHAR.L income_statement (annual, 2024-12-31) — Reconciled Depreciation: 47300000.00
PHAR.L cash_flow (annual, 2024-12-31) — Repayment Of Debt: -41400000.00
PHAR.L cash_flow (annual, 2024-12-31) — Repurchase Of Capital Stock: -3800000.00
PHAR.L balance_sheet (annual, 2024-12-31) — Restricted Cash: 100000.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Restricted Cash: 100000.00
PHAR.L income_statement (annual, 2024-12-31) — Restructuring And Mergern Acquisition: 600000.00
PHAR.L balance_sheet (annual, 2024-12-31) — Retained Earnings: -53500000.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Retained Earnings: -53500000.00
PHAR.L income_statement (annual, 2024-12-31) — Selling General And Administration: 9100000.00
PHAR.L balance_sheet (annual, 2024-12-31) — Share Issued: 424178662.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Share Issued: 424178662.00
PHAR.L cash_flow (annual, 2024-12-31) — Short Term Debt Issuance: 2200000.00
PHAR.L income_statement (annual, 2024-12-31) — Special Income Charges: 25700000.00
PHAR.L cash_flow (annual, 2024-12-31) — Stock Based Compensation: 900000.00
PHAR.L balance_sheet (annual, 2024-12-31) — Stockholders Equity: 295700000.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Stockholders Equity: 295700000.00
PHAR.L balance_sheet (annual, 2024-12-31) — Tangible Book Value: 295700000.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Tangible Book Value: 295700000.00
PHAR.L income_statement (annual, 2024-12-31) — Tax Effect Of Unusual Items: 6500000.00
PHAR.L income_statement (annual, 2024-12-31) — Tax Provision: 37100000.00
PHAR.L income_statement (annual, 2024-12-31) — Tax Rate For Calcs: 0.25
PHAR.L balance_sheet (annual, 2024-12-31) — Taxes Receivable: 300000.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Taxes Receivable: 300000.00
PHAR.L cash_flow (annual, 2024-12-31) — Taxes Refund Paid: -37200000.00
PHAR.L balance_sheet (annual, 2024-12-31) — Total Assets: 427300000.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Total Assets: 427300000.00
PHAR.L balance_sheet (annual, 2024-12-31) — Total Capitalization: 295700000.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Total Capitalization: 295700000.00
PHAR.L balance_sheet (annual, 2024-12-31) — Total Debt: 200000.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Total Debt: 200000.00
PHAR.L balance_sheet (annual, 2024-12-31) — Total Equity Gross Minority Interest: 295700000.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Total Equity Gross Minority Interest: 295700000.00
PHAR.L income_statement (annual, 2024-12-31) — Total Expenses: 97800000.00
PHAR.L balance_sheet (annual, 2024-12-31) — Total Liabilities Net Minority Interest: 131600000.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Total Liabilities Net Minority Interest: 131600000.00
PHAR.L balance_sheet (annual, 2024-12-31) — Total Non Current Assets: 353300000.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Total Non Current Assets: 353300000.00
PHAR.L balance_sheet (annual, 2024-12-31) — Total Non Current Liabilities Net Minority Interest: 113900000.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Total Non Current Liabilities Net Minority Interest: 113900000.00
PHAR.L income_statement (annual, 2024-12-31) — Total Operating Income As Reported: 64300000.00
PHAR.L balance_sheet (annual, 2024-12-31) — Total Tax Payable: 5300000.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Total Tax Payable: 5300000.00
PHAR.L income_statement (annual, 2024-12-31) — Total Unusual Items: 26000000.00
PHAR.L income_statement (annual, 2024-12-31) — Total Unusual Items Excluding Goodwill: 26000000.00
PHAR.L balance_sheet (annual, 2024-12-31) — Tradeand Other Payables Non Current: 200000.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Tradeand Other Payables Non Current: 200000.00
PHAR.L balance_sheet (annual, 2024-12-31) — Treasury Shares Number: 12906674.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Treasury Shares Number: 12906674.00
PHAR.L balance_sheet (annual, 2024-12-31) — Treasury Stock: 41300000.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Treasury Stock: 41300000.00
PHAR.L balance_sheet (annual, 2024-12-31) — Working Capital: 56300000.00
PHAR.L balance_sheet (quarterly, 2024-12-31) — Working Capital: 56300000.00
PHAR.L balance_sheet (quarterly, 2025-06-30) — Accounts Payable: 12300000.00
PHAR.L balance_sheet (quarterly, 2025-06-30) — Accounts Receivable: 52900000.00
PHAR.L balance_sheet (quarterly, 2025-06-30) — Additional Paid In Capital: 58000000.00
PHAR.L balance_sheet (quarterly, 2025-06-30) — Capital Lease Obligations: 200000.00
PHAR.L balance_sheet (quarterly, 2025-06-30) — Capital Stock: 33000000.00
PHAR.L balance_sheet (quarterly, 2025-06-30) — Cash And Cash Equivalents: 22600000.00
PHAR.L balance_sheet (quarterly, 2025-06-30) — Cash Cash Equivalents And Short Term Investments: 22600000.00
PHAR.L balance_sheet (quarterly, 2025-06-30) — Common Stock: 33000000.00
PHAR.L balance_sheet (quarterly, 2025-06-30) — Common Stock Equity: 291800000.00
PHAR.L balance_sheet (quarterly, 2025-06-30) — Current Assets: 80400000.00
PHAR.L balance_sheet (quarterly, 2025-06-30) — Current Capital Lease Obligation: 200000.00
PHAR.L balance_sheet (quarterly, 2025-06-30) — Current Debt: 0.00
PHAR.L balance_sheet (quarterly, 2025-06-30) — Current Debt And Capital Lease Obligation: 200000.00
PHAR.L balance_sheet (quarterly, 2025-06-30) — Current Liabilities: 15300000.00
PHAR.L balance_sheet (quarterly, 2025-06-30) — Goodwill And Other Intangible Assets: 23700000.00
PHAR.L balance_sheet (quarterly, 2025-06-30) — Gross PPE: 257800000.00
PHAR.L balance_sheet (quarterly, 2025-06-30) — Hedging Assets Current: 200000.00
PHAR.L balance_sheet (quarterly, 2025-06-30) — Inventory: 4300000.00
PHAR.L balance_sheet (quarterly, 2025-06-30) — Invested Capital: 291800000.00
PHAR.L balance_sheet (quarterly, 2025-06-30) — Long Term Capital Lease Obligation: 0.00
PHAR.L balance_sheet (quarterly, 2025-06-30) — Long Term Debt And Capital Lease Obligation: 0.00
PHAR.L balance_sheet (quarterly, 2025-06-30) — Long Term Provisions: 53200000.00
PHAR.L balance_sheet (quarterly, 2025-06-30) — Net PPE: 257800000.00
PHAR.L balance_sheet (quarterly, 2025-06-30) — Net Tangible Assets: 268100000.00
PHAR.L balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Taxes Liabilities: 59400000.00
PHAR.L balance_sheet (quarterly, 2025-06-30) — Ordinary Shares Number: 411839529.00
PHAR.L balance_sheet (quarterly, 2025-06-30) — Other Non Current Assets: 57800000.00
PHAR.L balance_sheet (quarterly, 2025-06-30) — Other Properties: 200000.00
PHAR.L balance_sheet (quarterly, 2025-06-30) — Payables: 15100000.00
PHAR.L balance_sheet (quarterly, 2025-06-30) — Properties: 257600000.00
PHAR.L balance_sheet (quarterly, 2025-06-30) — Retained Earnings: -58300000.00
PHAR.L balance_sheet (quarterly, 2025-06-30) — Share Issued: 411839529.00
PHAR.L balance_sheet (quarterly, 2025-06-30) — Stockholders Equity: 291800000.00
PHAR.L balance_sheet (quarterly, 2025-06-30) — Tangible Book Value: 268100000.00
PHAR.L balance_sheet (quarterly, 2025-06-30) — Taxes Receivable: 400000.00
PHAR.L balance_sheet (quarterly, 2025-06-30) — Total Assets: 419700000.00
PHAR.L balance_sheet (quarterly, 2025-06-30) — Total Capitalization: 291800000.00
PHAR.L balance_sheet (quarterly, 2025-06-30) — Total Debt: 200000.00
PHAR.L balance_sheet (quarterly, 2025-06-30) — Total Equity Gross Minority Interest: 291800000.00
PHAR.L balance_sheet (quarterly, 2025-06-30) — Total Liabilities Net Minority Interest: 127900000.00
PHAR.L balance_sheet (quarterly, 2025-06-30) — Total Non Current Assets: 339300000.00
PHAR.L balance_sheet (quarterly, 2025-06-30) — Total Non Current Liabilities Net Minority Interest: 112600000.00
PHAR.L balance_sheet (quarterly, 2025-06-30) — Total Tax Payable: 2800000.00
PHAR.L balance_sheet (quarterly, 2025-06-30) — Working Capital: 65100000.00
PHAR.L income_statement (annual, 2025-12-31) — +Operating Expense: 9200000.00
PHAR.L income_statement (annual, 2025-12-31) — +Total Revenue: 114600000.00
PHAR.L balance_sheet (annual, 2025-12-31) — Accounts Receivable: 14600000.00
PHAR.L balance_sheet (quarterly, 2025-12-31) — Accounts Receivable: 14600000.00
PHAR.L balance_sheet (annual, 2025-12-31) — Accumulated Depreciation: -901000000.00
PHAR.L balance_sheet (quarterly, 2025-12-31) — Accumulated Depreciation: -901000000.00
PHAR.L balance_sheet (annual, 2025-12-31) — Additional Paid In Capital: 160800000.00
PHAR.L balance_sheet (quarterly, 2025-12-31) — Additional Paid In Capital: 160800000.00
PHAR.L income_statement (annual, 2025-12-31) — Average Dilution Earnings: 0.00
PHAR.L income_statement (annual, 2025-12-31) — Basic Average Shares: 413100000.00
PHAR.L income_statement (annual, 2025-12-31) — Basic EPS: -0.02
PHAR.L cash_flow (annual, 2025-12-31) — Beginning Cash Position: 16500000.00
PHAR.L cash_flow (annual, 2025-12-31) — Capital Expenditure: -23700000.00
PHAR.L balance_sheet (annual, 2025-12-31) — Capital Lease Obligations: 0.00
PHAR.L balance_sheet (quarterly, 2025-12-31) — Capital Lease Obligations: 0.00
PHAR.L balance_sheet (annual, 2025-12-31) — Capital Stock: 32400000.00
PHAR.L balance_sheet (quarterly, 2025-12-31) — Capital Stock: 32400000.00
PHAR.L balance_sheet (annual, 2025-12-31) — Cash And Cash Equivalents: 35400000.00
PHAR.L balance_sheet (quarterly, 2025-12-31) — Cash And Cash Equivalents: 35400000.00
PHAR.L balance_sheet (annual, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 35400000.00
PHAR.L balance_sheet (quarterly, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 35400000.00
PHAR.L cash_flow (annual, 2025-12-31) — Cash Dividends Paid: -6500000.00
PHAR.L cash_flow (annual, 2025-12-31) — Change In Inventory: 3200000.00
PHAR.L cash_flow (annual, 2025-12-31) — Change In Payable: -400000.00
PHAR.L cash_flow (annual, 2025-12-31) — Change In Receivables: 26200000.00
PHAR.L cash_flow (annual, 2025-12-31) — Change In Working Capital: 29000000.00
PHAR.L cash_flow (annual, 2025-12-31) — Changes In Cash: 23900000.00
PHAR.L balance_sheet (annual, 2025-12-31) — Common Stock: 32400000.00
PHAR.L balance_sheet (quarterly, 2025-12-31) — Common Stock: 32400000.00
PHAR.L cash_flow (annual, 2025-12-31) — Common Stock Dividend Paid: -6500000.00
PHAR.L balance_sheet (annual, 2025-12-31) — Common Stock Equity: 283900000.00
PHAR.L balance_sheet (quarterly, 2025-12-31) — Common Stock Equity: 283900000.00
PHAR.L cash_flow (annual, 2025-12-31) — Common Stock Payments: -300000.00
PHAR.L income_statement (annual, 2025-12-31) — Cost Of Revenue: 96400000.00
PHAR.L balance_sheet (annual, 2025-12-31) — Current Assets: 66200000.00
PHAR.L balance_sheet (quarterly, 2025-12-31) — Current Assets: 66200000.00
PHAR.L balance_sheet (annual, 2025-12-31) — Current Capital Lease Obligation: 0.00
PHAR.L balance_sheet (quarterly, 2025-12-31) — Current Capital Lease Obligation: 0.00
PHAR.L balance_sheet (annual, 2025-12-31) — Current Debt And Capital Lease Obligation: 0.00
PHAR.L balance_sheet (quarterly, 2025-12-31) — Current Debt And Capital Lease Obligation: 0.00
PHAR.L balance_sheet (annual, 2025-12-31) — Current Liabilities: 16100000.00
PHAR.L balance_sheet (quarterly, 2025-12-31) — Current Liabilities: 16100000.00
PHAR.L cash_flow (annual, 2025-12-31) — Depreciation: 46600000.00
PHAR.L cash_flow (annual, 2025-12-31) — Depreciation And Amortization: 46600000.00
PHAR.L income_statement (annual, 2025-12-31) — Diluted Average Shares: 413100000.00
PHAR.L income_statement (annual, 2025-12-31) — Diluted EPS: -0.02
PHAR.L income_statement (annual, 2025-12-31) — Diluted NI Availto Com Stockholders: -6600000.00
PHAR.L cash_flow (annual, 2025-12-31) — Dividends Received Cfi: 0.00
PHAR.L income_statement (annual, 2025-12-31) — EBIT: 8800000.00
PHAR.L income_statement (annual, 2025-12-31) — EBITDA: 55400000.00
PHAR.L cash_flow (annual, 2025-12-31) — Effect Of Exchange Rate Changes: -200000.00
PHAR.L cash_flow (annual, 2025-12-31) — End Cash Position: 40200000.00
PHAR.L cash_flow (annual, 2025-12-31) — Financing Cash Flow: -7000000.00
PHAR.L cash_flow (annual, 2025-12-31) — Free Cash Flow: 31900000.00
PHAR.L income_statement (annual, 2025-12-31) — General And Administrative Expense: 8800000.00
PHAR.L balance_sheet (annual, 2025-12-31) — Gross PPE: 1177900000.00
PHAR.L balance_sheet (quarterly, 2025-12-31) — Gross PPE: 1177900000.00
PHAR.L income_statement (annual, 2025-12-31) — Gross Profit: 18200000.00
PHAR.L balance_sheet (annual, 2025-12-31) — Hedging Assets Current: 0.00
PHAR.L balance_sheet (quarterly, 2025-12-31) — Hedging Assets Current: 0.00
PHAR.L income_statement (annual, 2025-12-31) — Impairment Of Capital Assets: 0.00
PHAR.L income_statement (annual, 2025-12-31) — Interest Expense: 2300000.00
PHAR.L income_statement (annual, 2025-12-31) — Interest Expense Non Operating: 2300000.00
PHAR.L cash_flow (annual, 2025-12-31) — Interest Paid Cff: 0.00
PHAR.L cash_flow (annual, 2025-12-31) — Interest Paid Cfo: -100000.00
PHAR.L cash_flow (annual, 2025-12-31) — Interest Received Cfo: 500000.00
PHAR.L balance_sheet (annual, 2025-12-31) — Inventory: 6100000.00
PHAR.L balance_sheet (quarterly, 2025-12-31) — Inventory: 6100000.00
PHAR.L balance_sheet (annual, 2025-12-31) — Invested Capital: 283900000.00
PHAR.L balance_sheet (quarterly, 2025-12-31) — Invested Capital: 283900000.00
PHAR.L cash_flow (annual, 2025-12-31) — Investing Cash Flow: -24700000.00
PHAR.L balance_sheet (annual, 2025-12-31) — Investmentsin Subsidiariesat Cost: 0.00
PHAR.L balance_sheet (quarterly, 2025-12-31) — Investmentsin Subsidiariesat Cost: 0.00
PHAR.L cash_flow (annual, 2025-12-31) — Issuance Of Debt: 0.00
PHAR.L cash_flow (annual, 2025-12-31) — Long Term Debt Payments: 0.00
PHAR.L balance_sheet (annual, 2025-12-31) — Long Term Equity Investment: 0.00
PHAR.L balance_sheet (quarterly, 2025-12-31) — Long Term Equity Investment: 0.00
PHAR.L balance_sheet (annual, 2025-12-31) — Long Term Provisions: 56500000.00
PHAR.L balance_sheet (quarterly, 2025-12-31) — Long Term Provisions: 56500000.00
PHAR.L cash_flow (annual, 2025-12-31) — Net Business Purchase And Sale: 0.00
PHAR.L cash_flow (annual, 2025-12-31) — Net Common Stock Issuance: -300000.00
PHAR.L income_statement (annual, 2025-12-31) — Net Income: -6600000.00
PHAR.L income_statement (annual, 2025-12-31) — Net Income Common Stockholders: -6600000.00
PHAR.L income_statement (annual, 2025-12-31) — Net Income Continuous Operations: -6600000.00
PHAR.L income_statement (annual, 2025-12-31) — Net Income From Continuing And Discontinued Operation: -6600000.00
PHAR.L income_statement (annual, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: -6600000.00
PHAR.L cash_flow (annual, 2025-12-31) — Net Income From Continuing Operations: 8700000.00
PHAR.L income_statement (annual, 2025-12-31) — Net Income Including Noncontrolling Interests: -6600000.00
PHAR.L cash_flow (annual, 2025-12-31) — Net Intangibles Purchase And Sale: -7600000.00
PHAR.L income_statement (annual, 2025-12-31) — Net Interest Income: -2300000.00
PHAR.L cash_flow (annual, 2025-12-31) — Net Issuance Payments Of Debt: 0.00
PHAR.L cash_flow (annual, 2025-12-31) — Net Long Term Debt Issuance: 0.00
PHAR.L income_statement (annual, 2025-12-31) — Net Non Operating Interest Income Expense: -2300000.00
PHAR.L cash_flow (annual, 2025-12-31) — Net Other Investing Changes: -1000000.00
PHAR.L balance_sheet (annual, 2025-12-31) — Net PPE: 276900000.00
PHAR.L balance_sheet (quarterly, 2025-12-31) — Net PPE: 276900000.00
PHAR.L cash_flow (annual, 2025-12-31) — Net PPE Purchase And Sale: -16100000.00
PHAR.L cash_flow (annual, 2025-12-31) — Net Short Term Debt Issuance: 0.00
PHAR.L balance_sheet (annual, 2025-12-31) — Net Tangible Assets: 283900000.00
PHAR.L balance_sheet (quarterly, 2025-12-31) — Net Tangible Assets: 283900000.00
PHAR.L balance_sheet (annual, 2025-12-31) — Non Current Deferred Taxes Liabilities: 46500000.00
PHAR.L balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Taxes Liabilities: 46500000.00
PHAR.L income_statement (annual, 2025-12-31) — Normalized EBITDA: 56200000.00
PHAR.L income_statement (annual, 2025-12-31) — Normalized Income: -6000000.00
PHAR.L cash_flow (annual, 2025-12-31) — Operating Cash Flow: 55600000.00
PHAR.L income_statement (annual, 2025-12-31) — Operating Income: 9000000.00
PHAR.L income_statement (annual, 2025-12-31) — Operating Revenue: 114600000.00
PHAR.L balance_sheet (annual, 2025-12-31) — Ordinary Shares Number: 414117372.00
PHAR.L balance_sheet (quarterly, 2025-12-31) — Ordinary Shares Number: 414117372.00
PHAR.L balance_sheet (annual, 2025-12-31) — Other Equity Interest: 3400000.00
PHAR.L balance_sheet (quarterly, 2025-12-31) — Other Equity Interest: 3400000.00
PHAR.L income_statement (annual, 2025-12-31) — Other Operating Expenses: 400000.00
PHAR.L balance_sheet (annual, 2025-12-31) — Other Payable: 9400000.00
PHAR.L balance_sheet (quarterly, 2025-12-31) — Other Payable: 9400000.00
PHAR.L balance_sheet (annual, 2025-12-31) — Other Properties: 1300000.00
PHAR.L balance_sheet (quarterly, 2025-12-31) — Other Properties: 1300000.00
PHAR.L balance_sheet (annual, 2025-12-31) — Other Receivables: 4800000.00
PHAR.L balance_sheet (quarterly, 2025-12-31) — Other Receivables: 4800000.00
PHAR.L income_statement (annual, 2025-12-31) — Otherunder Preferred Stock Dividend: 0.00
PHAR.L balance_sheet (annual, 2025-12-31) — Payables: 12800000.00
PHAR.L balance_sheet (quarterly, 2025-12-31) — Payables: 12800000.00
PHAR.L income_statement (annual, 2025-12-31) — Pretax Income: 6500000.00
PHAR.L balance_sheet (annual, 2025-12-31) — Properties: 1176600000.00
PHAR.L balance_sheet (quarterly, 2025-12-31) — Properties: 1176600000.00
PHAR.L cash_flow (annual, 2025-12-31) — Purchase Of Business: 0.00
PHAR.L cash_flow (annual, 2025-12-31) — Purchase Of Intangibles: -7600000.00
PHAR.L cash_flow (annual, 2025-12-31) — Purchase Of PPE: -16100000.00
PHAR.L balance_sheet (annual, 2025-12-31) — Raw Materials: 6100000.00
PHAR.L balance_sheet (quarterly, 2025-12-31) — Raw Materials: 6100000.00
PHAR.L income_statement (annual, 2025-12-31) — Reconciled Cost Of Revenue: 96400000.00
PHAR.L income_statement (annual, 2025-12-31) — Reconciled Depreciation: 46600000.00
PHAR.L cash_flow (annual, 2025-12-31) — Repayment Of Debt: 0.00
PHAR.L cash_flow (annual, 2025-12-31) — Repurchase Of Capital Stock: -300000.00
PHAR.L balance_sheet (annual, 2025-12-31) — Restricted Cash: 4800000.00
PHAR.L balance_sheet (quarterly, 2025-12-31) — Restricted Cash: 4800000.00
PHAR.L income_statement (annual, 2025-12-31) — Restructuring And Mergern Acquisition: 300000.00
PHAR.L balance_sheet (annual, 2025-12-31) — Retained Earnings: -105900000.00
PHAR.L balance_sheet (quarterly, 2025-12-31) — Retained Earnings: -105900000.00
PHAR.L income_statement (annual, 2025-12-31) — Selling General And Administration: 8800000.00
PHAR.L balance_sheet (annual, 2025-12-31) — Share Issued: 416320478.00
PHAR.L balance_sheet (quarterly, 2025-12-31) — Share Issued: 416320478.00
PHAR.L cash_flow (annual, 2025-12-31) — Short Term Debt Issuance: 0.00
PHAR.L income_statement (annual, 2025-12-31) — Special Income Charges: -300000.00
PHAR.L cash_flow (annual, 2025-12-31) — Stock Based Compensation: 1600000.00
PHAR.L balance_sheet (annual, 2025-12-31) — Stockholders Equity: 283900000.00
PHAR.L balance_sheet (quarterly, 2025-12-31) — Stockholders Equity: 283900000.00
PHAR.L balance_sheet (annual, 2025-12-31) — Tangible Book Value: 283900000.00
PHAR.L balance_sheet (quarterly, 2025-12-31) — Tangible Book Value: 283900000.00
PHAR.L income_statement (annual, 2025-12-31) — Tax Effect Of Unusual Items: -200000.00
PHAR.L income_statement (annual, 2025-12-31) — Tax Provision: 13100000.00
PHAR.L income_statement (annual, 2025-12-31) — Tax Rate For Calcs: 0.25
PHAR.L balance_sheet (annual, 2025-12-31) — Taxes Receivable: 500000.00
PHAR.L balance_sheet (quarterly, 2025-12-31) — Taxes Receivable: 500000.00
PHAR.L cash_flow (annual, 2025-12-31) — Taxes Refund Paid: -30700000.00
PHAR.L balance_sheet (annual, 2025-12-31) — Total Assets: 403000000.00
PHAR.L balance_sheet (quarterly, 2025-12-31) — Total Assets: 403000000.00
PHAR.L balance_sheet (annual, 2025-12-31) — Total Capitalization: 283900000.00
PHAR.L balance_sheet (quarterly, 2025-12-31) — Total Capitalization: 283900000.00
PHAR.L balance_sheet (annual, 2025-12-31) — Total Debt: 0.00
PHAR.L balance_sheet (quarterly, 2025-12-31) — Total Debt: 0.00
PHAR.L balance_sheet (annual, 2025-12-31) — Total Equity Gross Minority Interest: 283900000.00
PHAR.L balance_sheet (quarterly, 2025-12-31) — Total Equity Gross Minority Interest: 283900000.00
PHAR.L income_statement (annual, 2025-12-31) — Total Expenses: 105600000.00
PHAR.L balance_sheet (annual, 2025-12-31) — Total Liabilities Net Minority Interest: 119100000.00
PHAR.L balance_sheet (quarterly, 2025-12-31) — Total Liabilities Net Minority Interest: 119100000.00
PHAR.L balance_sheet (annual, 2025-12-31) — Total Non Current Assets: 336800000.00
PHAR.L balance_sheet (quarterly, 2025-12-31) — Total Non Current Assets: 336800000.00
PHAR.L balance_sheet (annual, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 103000000.00
PHAR.L balance_sheet (quarterly, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 103000000.00
PHAR.L income_statement (annual, 2025-12-31) — Total Operating Income As Reported: 8700000.00
PHAR.L balance_sheet (annual, 2025-12-31) — Total Tax Payable: 3400000.00
PHAR.L balance_sheet (quarterly, 2025-12-31) — Total Tax Payable: 3400000.00
PHAR.L income_statement (annual, 2025-12-31) — Total Unusual Items: -800000.00
PHAR.L income_statement (annual, 2025-12-31) — Total Unusual Items Excluding Goodwill: -800000.00
PHAR.L balance_sheet (annual, 2025-12-31) — Treasury Shares Number: 2203106.00
PHAR.L balance_sheet (quarterly, 2025-12-31) — Treasury Shares Number: 2203106.00
PHAR.L balance_sheet (annual, 2025-12-31) — Treasury Stock: 600000.00
PHAR.L balance_sheet (quarterly, 2025-12-31) — Treasury Stock: 600000.00
PHAR.L balance_sheet (annual, 2025-12-31) — Working Capital: 50100000.00
PHAR.L balance_sheet (quarterly, 2025-12-31) — Working Capital: 50100000.00
PHARM.AS balance_sheet (annual, 2021-12-31) — Available For Sale Securities: 1449000.00
PHARM.AS cash_flow (annual, 2021-12-31) — Common Stock Issuance: 4718000.00
PHARM.AS cash_flow (annual, 2021-12-31) — Gain Loss On Sale Of Business: 0.00
PHARM.AS income_statement (annual, 2021-12-31) — Gain On Sale Of Business: 0.00
PHARM.AS balance_sheet (annual, 2021-12-31) — Investments In Other Ventures Under Equity Method: 7201000.00
PHARM.AS cash_flow (annual, 2021-12-31) — Issuance Of Capital Stock: 4718000.00
PHARM.AS balance_sheet (annual, 2021-12-31) — Land And Improvements: 31000.00
PHARM.AS cash_flow (annual, 2021-12-31) — Net Common Stock Issuance: 4718000.00
PHARM.AS cash_flow (annual, 2021-12-31) — Net Other Financing Charges: -25000000.00
PHARM.AS balance_sheet (annual, 2021-12-31) — Other Non Current Liabilities: 165000.00
PHARM.AS balance_sheet (annual, 2021-12-31) — Other Payable: 34000.00